Post-Liver Transplant Metabolic Syndrome

Area of Science:

• Hepatology
• Transplantation Medicine
• Metabolic Disorders

Background:

• Non-alcoholic steatohepatitis (NASH) is a leading cause of liver transplantation.
• Metabolic syndrome is increasingly prevalent in liver transplant recipients, impacting graft survival.
• Recurrence and de novo non-alcoholic fatty liver disease (NAFLD) are common post-transplant, though fibrosis recurrence is minimal.

Purpose of the Study:

• To review the challenges of metabolic syndrome in liver transplant recipients.
• To discuss the pathogenesis, diagnosis, and prevention of recurrent and de novo NAFLD.
• To highlight the need for customized immunosuppression strategies and unique care for NASH patients post-transplant.

Main Methods:

• This is a review article.
• Literature search on post-transplant metabolic syndrome, NAFLD recurrence, and immunosuppression.
• Synthesis of current knowledge and clinical recommendations.

Main Results:

• Metabolic syndrome significantly impacts liver transplant recipients.
• Recurrent and de novo NAFLD are prevalent, but fibrosis recurrence is low.
• NASH patients post-transplant face increased risks of cardiovascular, renal events, and cancer.

Conclusions:

• Effective management of metabolic syndrome is crucial for liver allograft health.
• Tailored immunosuppression and vigilant monitoring are necessary for NASH patients.
• A unique, multidisciplinary care strategy is required for these high-risk patients.